News

Advocates ‘Roll’ on Capitol Hill for Disability Rights

In an effort to make sure those with spinal cord injuries and disorders (SCI/D) are included in disability legislation, the United Spinal Association and some 200 advocates recently gathered virtually for this year’s “Roll on Capitol Hill.” The annual event, in which advocates met with lawmakers, gives organization members…

MS-related Fatigue Strongly Affects Youngsters’ Functioning

Multiple sclerosis and its associated fatigue negatively affect school performance, mental health, and physical and social functioning in children and adolescents with the disease, according to a review study. Pediatric-onset multiple sclerosis (POMS) also was associated with negative effects on social functioning, mental health, and quality of life in…

Oral Aubagio Approved in EU for Children With RRMS, Ages 10-17

The European Commission (EC) has approved Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17, with relapsing-remitting multiple sclerosis (RRMS). Aubagio, approved for adults with RRMS since 2013, is now the first oral therapy available as a first-line treatment for pediatric patients in the European…

Results: Ponvory Outperforms Aubagio in OPTIMUM Clinical Trial

In the OPTIMUM clinical trial, Ponvory (ponesimod) significantly outperformed Aubagio (teriflunomide) in reducing relapse rates, fatigue, and evidence of brain damage among people with relapsing multiple sclerosis (MS). Based on these results, Ponvory has now been approved in the U.S. and the European Union as a treatment…

Younger Age, DMT Use at Early Relapse May Lessen Later Disability

People with  multiple sclerosis (MS) who are using a disease-modifying therapy — and are at a younger age — when they have a relapse within the first three years of their disease course are more likely to recover completely, lowering their risk of long-term, 10-year disability, a study suggests. Complete recovery…

$1M Gift Will Expand Adventure-based Healing Program

A $1 million gift from Velocity Global will help expand First Descents, an adventure program for young adults living with multiple sclerosis (MS) or other serious chronic conditions. The money will go toward program development and is expected to help First Descents reach 1,000 MS patients over…

Home-based Exercise Viable Alternative for RRMS Patients

A home-based rehabilitation program can help ease fatigue, improve motor and cognitive function, and promote better quality of life in people with relapsing-remitting multiple sclerosis (RRMS), a small clinical trial has found. While a structured supervised exercise program was better at improving fatigue and health-related quality of life, the…

FDA Rejects Expansion of Aubagio for Pediatric MS

The U.S. Food and Drug Administration (FDA) has rejected an application requesting the expansion of Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17, with relapsing forms of multiple sclerosis (MS). “The FDA deemed the data submitted were not sufficient to obtain approval of…

Shepherd Center, BurnAlong Open Global Online Rehab Classes for MS

BurnAlong and the Shepherd Center, a leading rehabilitation hospital in the U.S., have established a partnership to bring tailored rehabilitation classes to people with multiple sclerosis (MS) and other neuromuscular diseases worldwide. The video classes, designed by clinicians, therapists, and wellness professionals at the Shepherd Center, based in Atlanta,…

Meaningful Cognitive Gains in Pediatric MS Captured Using Pencil-Paper Test

A computer-based training program that exercises distinct components of attention and working memory can improve cognition in young people with pediatric-onset multiple sclerosis (POMS), a new study indicates. Findings also support a common pencil-and-paper measure of cognition, called the Symbol Digit Modalities Test (SDMT), in detecting clinically meaningful changes…

DMTs Underutilized in Younger Patients, Study Indicates

Nearly a third of people with multiple sclerosis (MS) who are younger than 40 are not being treated with disease-modifying treatments (DMTs), even though younger individuals are expected to get the most benefit from DMTs, according to a new study. “DMTs for MS are more frequently used at…

Robotic Exoskeleton Intervention Improves Motor, Cognitive Function

Four weeks of robotic exoskeleton-assisted exercise rehabilitation, called REAER, worked better than conventional gait training in improving mobility and cognitive function in multiple sclerosis (MS) patients with substantial walking difficulties, according to a small trial. A robotic exoskeleton consists of an externally worn device that encases a user’s hips, back,…

Impaired Social Cognition May Affect Well-being of RRMS Patients

Impaired social cognition — lacking the ability to understand and process others’ emotions — may affect how people with relapsing-remitting multiple sclerosis (RRMS) feel on a day-to-day basis, a small, three-year study has found. RRMS patients with such difficulties were “characterized at follow-up by a higher level of depression…

BelongMS App Now Includes French Language Option

Belong.Life, a developer of a networking platforms that help patients navigate and manage their disease, has added a French language option in its BelongMS app for the French-speaking Canadian community. BelongMS is a free mobile app that uses artificial intelligence algorithms to support the multiple sclerosis (MS)…

Qynapse Announces Research Collaborations for World MS Day

Qynapse, a company that combines artificial intelligence with neuroimaging technology, is reaffirming its commitment to help advance multiple sclerosis (MS) research and care in recognition of World MS Day. World MS Day is officially celebrated on May 30, with global events and activities designed to raise disease awareness.

Nasal Foralumab Led to Promising Immune Effects in Phase 1 Trial

Nasally-administered foralumab, a potential treatment for neurodegenerative disorders such as progressive forms of multiple sclerosis (MS), appears safe and well-tolerated, and shows immune-modulating and anti-inflammatory effects in healthy volunteers, an updated analysis from a Phase 1 trial has found. “Nasal administration of Foralumab is a unique approach to treat…

PicnicHealth, Komodo Pool Real-world Data for Research

PicnicHealth and Komodo Health have agreed to combine their databases of patient medical records to support research based on real-world evidence. Together, the companies hope to unlock new insights into complex diseases like multiple sclerosis (MS). “Komodo Health and PicnicHealth share a mission to utilize health data…

At-home Brain Stimulation Program Now Available

New York University (NYU) Langone Health has launched an at-home, therapeutic program of transcranial direct current stimulation (tDCS) — a type of non-invasive brain stimulation — to reduce cognitive, motor, speech, or mood symptoms associated with multiple sclerosis (MS) and other brain disorders. A first of its kind, the…

Mayzent, Zeposia May Lose Ground in Canada, Report Finds

Mayzent (siponimod) and Zeposia (ozanimod), the two sphingosine-1-phosphate (S1P) receptor modulators most recently approved in Canada for treating multiple sclerosis (MS), showed strong launches in the country, according to the latest Spherix Global Insights’ report. However, due to several internal and external factors, sustained relevance of these…

Immersive Virtual Reality May Improve Treadmill Gait Training

Immersive virtual reality may make treadmill exercise more engaging and effective for people with multiple sclerosis (MS) or other conditions that can make walking difficult, according to new research. The findings were published in the Journal of NeuroEngineering and Rehabilitation, in the study “Immersive virtual reality…

First SPMS Patient Dosed With Foralumab Nasal Spray

Foralumab, an investigational anti-CD3 antibody that is administered via a nasal spray, has been given for the first time to a person with secondary progressive multiple sclerosis (SPMS). It was administered under an Individual Patient Expanded Access Program, which earned approval from the U.S. Food and Drug Administration in…

Ponvory Approved in EU for Active Relapsing Forms of MS

The European Commission has approved Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis (MS) and active disease, as defined by clinical or imaging features. The approval, which follows a recommendation from the Committee for Medicinal Products for Human Use in March, covers clinically isolated…